Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International)

LONDON – Algeta A/S said its lead product Alpharadin is on course for blockbuster status after the Phase III trial was stopped on the basis of statistically significant efficacy in the treatment of bone marrow metastases in patients with castration-resistant prostate cancer. (BioWorld International)